PDCD1 and nasopharyngeal carcinoma: In China, NPC is mainly undifferentiated non-keratinizing carcinoma, with a PD-L1 positivity rate of over 95%, providing an important theoretical basis for anti-PD-1/PD-L1 antibody therapy for NPC 7-9.